2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (2SHOTS)

Prostate cancer is one of the most common cancers in men. Traditional radiotherapy involves weeks of daily treatment sessions, which can be time-consuming and burdensome. Recent advances have shown that delivering radiation in fewer but larger doses — called stereotactic ablative radiotherapy (SABR) — is equally effective. Standard prostate SABR uses 5 treatments. This study asks: can we do it in just 2? This Australian Phase 2 trial is testing 2-fraction SABR for men with intermediate-risk localised prostate cancer. Researchers will carefully monitor side effects (especially urinary and bowel symptoms) and quality of life to make sure this ultra-short approach is safe and doesn't compromise outcomes. If successful, it would make treatment far more convenient for patients and reduce healthcare costs. You may be eligible if you are a man aged 18 or older with intermediate-risk prostate cancer (certain PSA levels, Grade Group 2–3, or clinical stage T2b/c) and no signs of spread to nodes or distant sites. Men with severe urinary symptoms, prior pelvic radiation, prostate over 100cc, or contraindications to MRI are not eligible.